PF-06291874

DB15065InvestigationalSmall molecule

PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).

Mechanism: Pharmacologically active on Glucagon receptor
Curator reviewed
Formula / weight: C₂₆H₂₈F₃N₃O₄ · 503.522 g/mol (avg)
Code names: PF-06291874

Resolves to

Compound

UNIICGY4I8F278CAS1393124-08-7ChEMBLCHEMBL2381848

Structure

InChIKeyIBDYYOQKQCCSDP-QFIPXVFZSA-NSMILESCCC[C@H](OC1=CC(C)=C(N2C=C(C=N2)C(F)(F)F)C(C)=C1)C1=CC=C(C=C1)C(=O)NCCC(O)=O

Targets

P47871GCGR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with PF-06291874, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account